Yüklüyor......
Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
BACKGROUND: Sorafenib has been recommended as the first-line treatment and shown to prolong median overall survival (OS) of patients with advanced unresectable hepatocellular carcinoma (HCC). Recently, a growing amount of research has supported the application of transarterial chemoembolization (TAC...
Kaydedildi:
| Yayımlandı: | Ann Transl Med |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AME Publishing Company
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7290559/ https://ncbi.nlm.nih.gov/pubmed/32566614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2020.02.123 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|